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ARTICLE
Clinical Study
Randomised phase II trial of mFOLFOX6 plus bevacizumab
versus mFOLFOX6 plus cetuximab as first-line treatment for
colorectal liver metastasis (ATOM trial)
Eiji Oki 1, Yasunori Emi2, Takeharu Yamanaka3, Hiroyuki Uetake4, Kei Muro5, Takao Takahashi6, Takeshi Nagasaka7, Etsuro Hatano8,
Hitoshi Ojima9, Dai Manaka10, Tetsuya Kusumoto11, Yu Katayose12, Toshiyoshi Fujiwara13, Kazuhiro Yoshida6, Michiaki Unno14,
Ichinosuke Hyodo15, Naohiro Tomita16, Kenichi Sugihara4 and Yoshihiko Maehara17
BACKGROUND: Chemotherapy with biologics followed by liver surgery improves the resection rate and survival of patients with
colorectal liver metastasis (CRLM). However, no prospective study has compared the outcomes of chemotherapy with bevacizumab
(BEV) versus cetuximab (CET).
METHODS: The ATOM study is the first randomised trial comparing BEV and CET for initially unresectable CRLM. Patients were
randomly assigned in a 1:1 ratio to receive mFOLFOX6 plus either BEV or CET. The primary endpoint was progression-free survival
(PFS).
RESULTS: Between May 2013 and April 2016, 122 patients were enrolled. Median PFS was 11.5 months (95% CI 9.2–13.3 months) in
the BEV group and 14.8 months (95% CI 9.7–17.3 months) in the CET group (hazard ratio 0.803; P= 0.33). Patients with a smaller-
number but larger-sized metastases did better in the CET group. In the BEV and CET groups, the response rates were 68.4% and
84.7% and the resection rates were 56.1% and 49.2%, respectively.
CONCLUSION: Although CET achieved a better response rate than BEV for patients with a small number of large liver metastases,
both biologics had similar efficacy regarding liver resection and acceptable safety profiles. To achieve optimal PFS, biologics should
be selected in accordance with patient conditions.
TRIAL REGISTRATION: This trial is registered at ClinicalTrials.gov (number NCT01836653), and UMIN Clinical Trials Registry
(UMIN-CTR number UMIN000010209).
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BACKGROUND
Colorectal cancer (CRC) is the third most common cancer and the
second leading cause of cancer death worldwide.1 The 5-year
overall survival (OS) rate for the curatively resectable stages I–III of
CRC is almost 80% but is only 13% for stage IV CRC, which
accounts for approximately 18% of CRC diagnoses.2 Liver
metastases develop in almost 60% of patients with stage IV CRC
and in 9–13% of patients after curative resection of CRC.1,3 To
improve the prognosis of patients with CRC, outcomes for patients
with liver metastasis must be improved.
Among the treatment options for colorectal liver metastasis
(CRLM), liver resection is the most conducive to a cure, with 5-year
OS rates of 29–48%.4,5 Even for initially unresectable liver
metastasis, effective chemotherapy, along with targeted therapy,
sometimes enables resection of liver metastasis; Adam et al.
reported a 5-year OS rate of 33% for patients with unresectable
metastases who underwent surgery after chemotherapy.4 How-
ever, it is unclear which type of chemotherapy can best increase
resection rates and improve survival in patients with CRLM.
Several promising CRLM treatments have been reported,
including chemotherapy and molecular agents that target
epidermal growth factor receptor (EGFR) and vascular endothelial
growth factor (VEGF).6–10 Anti-EGFR drugs resulted in high
response and resection rates in the CELIM phase II trial and other
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studies for initially unresectable CRLM with wild-type KRAS.7,8,11
Anti-VEGF antibody regimens, such as mFOLFOX6 or CAPEOX plus
bevacizumab (BEV), have also showed high response and
resection rates in phase II studies.9,10,12 These reports suggest
that the combination of targeted agents and chemotherapy can
increase liver resection rates and response rates, thus improving
the progression-free survival (PFS) and OS of patients with CRLM.
However, no studies have compared anti-VEGF agents and anti-
EGFR agents for liver-limited RASwt CRLM.
The present randomised phase II clinical study (the ATOM trial)
aimed to compare mFOLFOX6 plus BEV versus mFOLFOX6 plus
cetuximab (CET) in patients with liver-limited RASwt CRLM.
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Fig. 1 Consort flow diagram. Primary analysis was evaluated in the full analysis set (FAS), which was defined as all patients who were eligible
for study inclusion, as well as those who received at least one dose of the protocol treatment
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METHODS
Patients
The ATOM trial was a multicentre, randomised phase II study
designed to evaluate the efficacy and safety of mFOLFOX6 plus
BEV and mFOLFOX6 plus CET in patients with liver-limited
metastases from wild-type (K)RAS CRC. Eligible criteria for the
study were (1) histopathologically confirmed CRC (adenocarci-
noma), excluding appendix and anal cancers; (2) no metastasis
other than to liver; (3) tumour tested to be KRASwt (between May
2013 and April 2015) or RASwt (between April 2015 and April
2016) (4) age between 20 and 80 years at the time of enrolment;
(5) Eastern Cooperative Oncology Group performance status of 0
or 1; (6) life expectancy of ≥3 months at the time of enrolment; (7)
sufficient organ function; and (8) signed informed consent.
Furthermore, each patient had to satisfy at least one of the
following criteria at enrolment: (a) ≥5 liver metastases, (b) a liver
metastasis with a maximum diameter ≥5 cm, (c) technically
inappropriate for resection in light of remaining hepatic function,
(d) invasion into all hepatic veins or the inferior vena cava, or (e)
invasion into both the right and left hepatic arteries or both of the
portal veins. The study was approved by the local ethics
committee of each participating centre and conducted in 63
Japanese institution.
Randomisation
Randomisation was based on dynamic allocation by a minimisa-
tion method in a centralised web-based system (EPS Corporation,
Tokyo, Japan). Allocation factors included: (1) synchronous liver
metastases with a primary lesion, synchronous liver metastases
without a primary lesion, or metachronous liver metastases; (2)
number of metastases (1–4 or ≥5); (3) maximum metastasis
diameter (≤5 or >5 cm); and (4) oxaliplatin used as adjuvant
chemotherapy.
Procedures
Patients received either mFOLFOX6 plus BEV (BEV 5mg/kg,
followed by oxaliplatin 85mg/m2, l-leucovorin 200mg/m2 and
bolus infusion of fluorouracil 400 mg/m2 on Day 1 and continuous
fluorouracil infusion 2400mg/m2 on Day 1 through Day 2) or
mFOLFOX6 plus CET (CET 400 mg/m2 as the initial dose and 250
mg/m2 as the subsequent doses on Days 1 and 8, followed by
mFOLFOX6), no later than 2 weeks after enrolment in the study.
Study treatments were continued in 2-week cycles until disease
progression. In accordance with the Response Evaluation Criteria
In Solid Tumours version 1.1, the same methods were used to
perform tumour assessment at baseline and every subsequent
8 weeks using torso contrast-enhanced computed tomography
(CT), liver contrast-enhanced magnetic resonance imaging, or
whole-body non-contrast CT. The tumour histopathological
response rate was defined as the proportion of patients with
grade ≥Ib in accordance with the following definition: grade 0, no
necrosis in the tumour; grade 1a, necrosis in <33.3% of the
tumour; grade 1b, necrosis in 33.3–66.6% of the tumour; grade 2,
necrosis in 66.6–<100% of the tumour; and grade 3, necrosis in
100% of the tumour.
Patients underwent liver resections if their metastases were
considered resectable, based on tumour assessments performed
after receiving at least 8 cycles of either protocol treatment. After
liver resection, a total of 12 cycles of the same chemotherapy plus
biologic agent as the preoperative treatment were recommended.
Surgery was performed at least 42 days after the last dose of BEV.
Statistical analysis
The primary endpoint was PFS, as assessed by the Independent
Central Review Committee (IRC). The cases were not censored at
the time of liver resection. Recurrence was considered to be a PFS
event in patients who underwent liver resection after protocol
treatment. Secondary endpoints included response rate, tumour
shrinkage at week 8, liver resection rate, time to treatment failure,
OS, quality of life, and adverse events (AEs).
We employed a selection design based on the hazard ratio
(HR). For 1-year PFS rates of the two arms to be 55% and 50%
(which corresponds to a HR of 0.862 under exponential
distribution), we needed 160 patients to select better treatment
in terms of an HR with a probability of 75%. Therefore, the initial
sample size was 160 in both arms. However, owing to slow
accrual of patients, the independent data monitoring committee
approved a reduction of the sample size in January 2015 to 120
patients in both arms; this would enable the observation of 84
PFS events, which would indicate a superior treatment with a
probability of 70%.
HRs for progression or death for CET versus BEV were estimated
using a Cox proportional-hazards model. Survival curves were
estimated using the Kaplan–Meier method. Statistical analyses
were performed using SAS version 9.4 (SAS Institute, Cary, USA).
RESULTS
Patients
Between May 2013 and April 2016, we screened 179 patients and
enrolled 122 patients from 63 sites in Japan (61 patients in each
arm). Figure 1 shows the consort flow diagram. Five patients (two
CET arm/three BEV arm) did not meet the criteria and a patient in
the BEV arm cannot be treated because of rapid disease
progression. Patient characteristics were well balanced between
the two arms (Table 1). Of the 116 patients, 2 patients in the BEV
arm were found to have RASmutations, while 1 patient in each arm
did not undergo RAS testing due to insufficient tumour samples.
Table 1. Patient characteristics
Variables mFOLFOX6
+BEV
mFOLFOX6
+CET
P
Age (years) Median (range) 64 (32.0–80.0) 65 (42.0–79.0) 0.328
Sex Male 34 (59.6%) 34 (57.6%) 0.825
Female 23 (40.4%) 25 (42.4%)
ECOG PS 0 51 (89.5%) 51 (86.4%) 0.616
1 6 (10.5%) 8 (13.6%)
Adjuvant
chemotherapy
Yes 3 (5.3%) 2 (3.4%) 0.619
Prior oxaliplatin Yes 1 (1.8%) 2 (3.4%) 0.579
Location
of tumour
Right 9 (15.8%) 14 (23.7%) 0.284
Left 48 (84.2%) 45 (76.3%)
Tumour status Synchro/
primary tumour
13 (22.8%) 15 (25.4%) 0.771
Synchro/no
primary
tumoura
39 (68.4%) 39 (66.1%)
Metachronous 5 (8.8%) 5 (8.5%)
Number of liver
metastases
<5 15 (26.3%) 18 (30.5%) 0.617
≥5 42 (73.7%) 41 (69.5%)
Diameter of
liver metastases
≤5 cm 20 (35.1%) 19 (32.2%) 0.742
>5 cm 37 (64.9%) 40 (67.8%)
mFOLFOX6 5-fluorouracil/folinic acid, oxaliplatin, BEV bevacizumab, CET
cetuximab, ECOG PS Eastern Cooperative Oncology Group
performance status
aSynchro/no primary tumour: metastatic tumour diagnosed within
6 months after resection of primary tumour
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Efficacy
On March 31, 2017, the median follow-up time was 24.3 months.
The median PFS assessed by the IRC for the CET arm was
14.8 months (95% confidence interval (CI): 9.7–17.3 months), while
for the BEV arm it was 11.5 months (95% CI: 9.2–13.3 months),
with a log-rank P value of 0.33. The PFS HR between the two arms
was 0.803 (95% CI: 0.513–1.256; Fig. 2a); PFS in accordance with
the investigators’ evaluations is shown in Supplementary Fig. S1.
The median OS in the BEV arm was 30.4 months but was not
achieved yet in Cmab arm (HR: 0.827, 95% CI: 0.437–1.564; Fig. 2b).
Subgroup analyses for the IRC PFS are shown in Fig. 3 Only in
patient with 1–4 liver metastasis the CET arm showed significant
HR, whereas PFS was better in the BEV arm among patients with
≥5 metastases. Kaplan–Meier curves of these subgroups are
shown in Supplementary Fig. S2A, B.
The overall response rate (ORR) for BEV was 68.4% (95% CI:
54.8%–80.1%), while the ORR for CET was 84.7% (95% CI:
73.0%–92.8%; P= 0.0483; Table 2). Median tumour shrinkage rates
at 8 weeks were 25.3% for BEV and 37.8% for CET. The waterfall plot
showing the best change in target lesion based on central
assessment is shown in Fig. 4. The overall resection rates including
R2 were 56.1% (32/57) for BEV and 49.2% (29/59) for CET, and
resection rates (R0+R1) were 49.1% (28/57) for BEV and 47.5%
(28/59) for CET (Table 2). Median PFS was assessed for patients with
R0/R1 status after study treatment followed by surgical resection;
median PFS for BEV was 6.5 months (95% CI: 4.0–13.6), while that for
CET it was 13.8 months (95% CI: 8.4–not reached), HR: 0.610 (95% CI:
0.298–1.245; Supplementary Fig. S3). Of the 57 tumours that were
assessable for histopathological analysis, the tumour histopatholo-
gical response rate (Grade 1b/2/3) was 66.6% (20/30) for BEV and
92.6% (25/27) for CET (P= 0.0229, Supplementary Table S1).
Safety
Grade ≥3 subjective or objective toxicity events occurred in
40.4% of the patients who received BEV and 52.5% of the
patients who received CET. The most frequently occurring AE of
grade ≥3 was neutropenia, with an incidence of 36.8% in the
BEV arm and 50.8% in the CET arm. Other AEs are presented in
Supplementary Table S2. AEs that caused discontinuation
occurred in 8 patients (13.1%) in the BEV arm and 6 (9.8%) in
the CET arm. No patient died from treatment-related AEs. In the
surgical safety population (n= 33 in the BEV arm and n= 29 in
the CET arm), all-grade surgery-related AEs according to the
Clavien–Dindo classification were reported in 8 patients (24.2%)
in the BEV arm and 12 (41.4%) in the CET arm. The most frequent
surgical AE was bile leakage, with an incidence of 18.2% in the
BEV arm and 24.1% in the CET arm. No grade 5 AEs were
reported (Supplementary Table S3).
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DISCUSSION
The anti-VEGF antibody BEV has an anti-angiogenic effect, which
elicits a specific morphologic tumour response of enhanced
necrosis, thus increasing the survival benefit of chemotherapy.13
Because of these benefits, some pivotal clinical studies reported
that combined therapy with cytotoxic drugs could potentially
improve CRC prognosis.10 A phase II study of patients with CRLM
reported that the anti-EGFR antibody CET was associated with an
improved response rate and a high liver resection rate.7,14–17
Although a few head-to-head randomised studies compared the
two antibodies in the whole population of patients with advanced
CRC, none of them led to a clear conclusion as to which agent was
better for the liver-limited CRLM.15,17–19 Our trial aimed to evaluate
the effect of an anti-EGFR antibody versus an anti-VEGF antibody
in patients with CRLM.
In our analysis, the median PFS (as assessed by the IRC) tended
to be better in the CET arm than in the BEV arm, but this
difference was not statistically significant. The ORR was also better
in the CET arm (84.7%) than the BEV arm (68.4%). However,
despite the higher ORR in the CET arm compared with the BEV
arm, the overall resection rate was similar in both arms. Although
the main results were equivocal, we can consider the results from
various angles.
Resection rate is often used as the primary endpoint for phase II
studies evaluating chemotherapy for CRLM. Previous studies have
reported similar resection rates to those achieved in our study.
One study reported a liver resection rate and ORR of FOLFOXIRI
+BEV of 51% and 81%, respectively,10 while the CELIM trial
reported that the resection rates of FOLFOX+CET and FOLFIRI
+CET were 51% and 49%, respectively.7 Furthermore, a review of
data from previous studies reported that response and resection
rates were positively correlated in CRLM and found the liver
resection rate to be 50–60% when the ORR is 80%.5 This
correlation is applicable to recent reports, including our study.
However, increasing the response rate >80% is a clinical challenge.
Therefore, the resection rate might not be an adequate surrogate
endpoint in further clinical studies of CRLM.
Subset analysis showed that, among patients with fewer
metastases (1–4), the CET group had better survival than the
BEV group (HR: 0.260, 95% CI: 0.084–0.811) but conversely among
patients with ≥5 metastases. Our inclusion criteria required that
patients with ≥5 metastases had tumours ≥5 cm in size. Therefore,
the presence of fewer but larger metastases might be a good
indication for the use of anti-EGFR antibody. Resection after
shrinkage of a large tumour is the ideal clinical course for CET-
treated patients. The New EPOC trial could not show any benefit
of adding CET to standard chemotherapy in patients with
resectable CRLM.20 However, this may be because CET is not
effective for small resectable liver metastases but seems suitable
for patients with fewer but larger metastases.
Number of liver metastatis
Hazard
ratio
Lower
limit
Upper
limit
Diameter of liver metastatis
Primary tumour at baseline
Location of primary tumour
Liver resection
Residual tumour
1–4 0.260 0.084 0.811
5– 1.219 0.745 1.995
≤5 cm 0.822 0.370 1.827
>5 cm 0.793 0.461 1.363
No 0.603 0.352 1.035
Yes 1.270 0.481 3.354
Left 0.491 1.361
Right 0.535 0.187 1.537
No 0.866 0.457 1.641
Yes 0.587 0.302 1.141
Other 0.888 0.506 1.559
R0 0.565 0.262 1.222
0.1 0.2 0.5 1 2 5 10
0.817
Favouring
Cetuximab
Favouring
Bevacizumab
Fig. 3 Forest plots show hazard ratios for progression-free survival in patients with colorectal to liver metastases, using mFOLFOX6
+bevacizumab and mFOLFOX6+cetuximab
Table 2. Overall response rates and liver resection rate
Overall response rates P
mFOLFOX6+BEV mFOLFOX6+CET
CR (%) 1 (1.8%) 1 (1.7%) —
PR (%) 38 (66.7%) 49 (83.1%) —
SD (%) 18 (31.6%) 6 (10.2%) —
PD (%) 0 (0.0%) 2 (3.4%) —
NE 0 (0.0%) 1 (1.7%) —
Overall response rate 68.4% 84.7% 0.0483
Disease control rate 100% 94.9% 0.2437
Liver resection rate
mFOLFOX6+BEV mFOLFOX6+CET
R0+R1 28 (49.1%) 28 (47.5%)
R0 25 (43.9%) 22 (37.3%)
R1 3 (5.3%) 6 (10.2%)
R2 4 (7.0%) 1 (1.7%)
All 32 (56.1%) 29 (49.2%)
Reasons for R2 Ablation: 2 Ablation and Residual: 1
Residual: 2
BEV bevacizumab, CET cetuximab, CR complete response, mFOLFOX6 5-
fluorouracil/folinic acid, oxaliplatin, NE not evaluable, PD progressive
disease, PR partial response, SD stable disease
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Tumour sidedness is also an important characteristic of
metastatic CRC. Although previous studies indicated no survival
benefit for CET in metastatic right-sided CRC,21 the PFS of patients
with right-sided tumours in our trial showed similar or better
results with CET as those with left-sided tumours. CET reportedly
reduces tumour size better than BEV, even in right-sided colon
cancer.22 Therefore, in cases with metastatic CRC limited to the
liver, sidedness might not be relevant for PFS, as half of the
metastatic site will be surgically resected.
A previous study reported a higher pathological response rate
for BEV than for CET.23 In contrast, the present study showed a
higher pathological response rate for CET than for BEV, which had
some effect on the survival of the patients who underwent
surgery. In fact, the median PFS of patients with surgical
conversion was 13.8 months (95% CI: 8.4–not reached) in the
CET arm and 6.5 months (95% CI: 4.0–13.6) in the BEV arm
(Supplementary Fig. S3). This difference will have some impact on
final overall survival. We will investigate tumour regression grade
(TRG), modified TRG, dangerous halo, and morphological response
as exploratory endpoints. These analyses will elucidate as to what
is the best pathological assessment of prognosis for CRLM.
The present trial was limited by its small sample size, and so the
statistical power was insufficient to enable the comparison of the
two biologic agents. Furthermore, the OS is immature and needs
longer-term follow-up. In addition, the inclusion criteria for initially
unresectable CRLM are controversial. We followed the criteria used
in previous studies, which included patients with CRLM with <5
metastases but with tumour(s) >5 cm in diameter.11,12 Some of
these cases might have been resectable without chemotherapy,
and this may have confounded the results.
In conclusion, CET showed a higher response rate than BEV
among patients with initially unresectable liver-limited metastases
and resulted in good PFS, especially for patients with fewer but
larger metastases. However, there were no significant differences
between BEV and CET in efficacy regarding resection rate, and both
biologic agents had acceptable safety profiles. Both agents are
viable treatment options for liver metastases with suboptimal
resectability.
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